Crucell corporate brochure (PDF)

Our business – Technologies
MAbstract® technology
MAbstract® technology is a human antibody-based phage display
system, which facilitates the discovery of novel drug targets and the
identification of human monoclonal antibody against those targets.
A phage (or ‘bacteriophage’) is a virus that can infect and multiply in
bacteria. In phage display technology, phages are genetically engineered
to expresses the pathogen-binding part of a human antibody on their
surfaces. In the application of MAbstract® technology, a library of
phages exposing a wide variety of human antibody fragments on their
surfaces is brought into contact with disease-causing microorganisms
(pathogens) or parts of pathogens in order to identify human antibodies
that selectively bind to targets of interest.
MAbstract® technology is an efficient method for the discovery of
human antibodies to be applied for the prevention, diagnosis and
therapy of diseases.
STAR® technology
STAR® technology is a gene expression technology. Acquired by Crucell
in 2004, it has proved extremely valuable for increasing production
of recombinant antibodies and therapeutic proteins on mammalian
cell lines. STAR® technology uses well-established mammalian cell banks
for protein and antibody production, thereby eliminating the need
for specially engineered mammalian cells. It allows for very rapid,
stable mammalian cell clone generation and typically generates stable
mammalian cell clones that produce 5 to 10 times more antibody or other
therapeutic protein than cell clones generated without STAR® technology.
Virosome technology
Virosome technology is a tool for developing novel vaccines against
infectious and chronic diseases. A virosome is a virus-like particle that
acts as a vaccine carrier and adjuvant (immunity enhancing) system.
Vaccines based on virosome technology combine high efficacy with
high purity, which means they are effective and safe to use even
in infants and individuals with a weakened immune system.
25